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Effects of Calcium Supplementation on Cardiovascular
Disease in Postmenopausal Women
RAIZEL ROBINSON
INTRODUCTION
In the United States, 53% of the population use dietary supplements. Of the people using
supplements, 43% use calcium and 37% use vitamin D. However, 63% of women older than 60
years of age reported using dietary supplements (Park et al., 2009). Calcium supplementation,
without co-administered vitamin D, increases the risk of myocardial infarction and cardiovascularrelated diseases among postmenopausal women. On the contrary, calcium supplementation with
accompanied vitamin D may not produce similar effects.
Postmenopausal women take calcium supplements in an attempt to prevent osteoporosis.
This is because postmenopausal women require a larger amount of calcium intake. Throughout
a person’s life, blood calcium levels continuously decrease due to greater loss of calcium via renal clearance (Tfelt-Hansen and Torring, 2004), reduced intestinal absorption and perhaps other
mechanisms. If the amount of calcium lost by the body consistently exceeds the amount absorbed,
than a loss of bone results (Hsia et al., 2007). A low calcium intake has been associated with an
increased risk of osteoporosis, bone fractures, and falls (Bailey et al., 2010). To compensate, postmenopausal women need up to 20% more calcium per day than their younger counterparts (Prince
et al., 2006). If the amount of calcium lost by the body consistently exceeds the amount absorbed,
than a loss of bone results (Hsia et al., 2007). Postmenopausal women take calcium supplements in
an attempt to prevent osteoporosis. Calcium is a major mineral component of the skeletal system.
Bone structure is maintained by the constant remolding of bone as it responds to the normal physiological and pathological skeletal stresses of daily living (Sahota, 2000). A low calcium intake
has been associated with an increased risk of osteoporosis, bone fractures, and falls (Bailey et al.,
2010).
Since vitamin D plays a role in absorption, these women also require excess vitamin D.
Many authoritative doctors and researchers recommend calcium supplements without considering the detrimental side effects that they may cause. Calcium and vitamin D supplements seem
ideal. They are pharmacologically active and cost-effective for the treatment of osteoporosis. In
addition, they have synergistic effects with antiabsortive agents on bone mass density in relation
to fracture prevention (Nieves, 2004). Based on these findings, doctors believed that these supplements can be administered indefinitely without detrimental side effects.
Currently, although researchers have found that calcium and supplements marginally reduce the risk of fractures in elderly women who are deficient in calcium and vitamin D, calcium
supplementation increases the risk of myocardial infarctions and heart disease (Bolland et al.,
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2010). Considering the detrimental effects that calcium may have on the cardiovascular system, it
is questionable whether calcium supplementation, in an effort to reduce osteoporosis, justified.
Mechanisms for Calcification in the Cardiovascular Vessels
Many mechanisms for calcium absorption have been suggested to explain its effects on
the risk of cardiovascular disease and myocardial infarctions. Calcium supplements can acutely
elevate serum calcium levels; possibly accelerating calcification in the walls of vascular structures.
Vascular calcification lends itself to the occurrence of vascular events such as myocardial infarction and coronary heart disease (Pentti et al., 2009). High calcium uptake has been associated
with vascular calcification and mortality in patients with end-stage renal disease (Giachelli, 2004).
However, this data may not be representative because of the age of the participants and reduced
renal function.
Calcium phosphate deposition, in the form of bioapatite, is the essential characteristic of
vascular calcification. This deposition can occur in the blood vessels, myocardium, and cardiac
valves. In the coronary arteries, calcification is positively correlated with an increased risk of
myocardial infarction and atherosclerotic plaque burden. It is possible that vascular calcification
initiates or progresses cardiovascular disease. Vascular calcification, especially calcification in the
tunica media of large arteries, leads to increased stiffening, and therefore decreased compliance
of the vessels. The resulting loss of important cushioning function of these arteries is a factor that
leads to impaired arterial distensibility, increased afterload favoring left ventricular hypertrophy,
compromised coronary perfusion, and hypermedial arterial calcification (Giachelli, 2004). Giachelli has suggested four different mechanisms for vascular calcification (refer to figure 1.). First,
blood vessel tissues normally express inhibitors of mineralization, such as pyrophosphate and
matrix gla protein. The lack of these molecules leads to spontaneous vascular calcification and

Figure 1. Schematic illustrating four, non–mutually exclusive theories for vascular calcification: (1)
loss of inhibition as a result of deficiency of constitutively expressed tissue-derived and circulating
mineralization inhibitors leads to default apatite deposition, (2) induction of bone formation resulting from altered differentiation of vascular smooth muscle or stem cells (3), circulating nucleational
complexes released from actively remodeling bone, and (4) cell death leading to release of apoptotic
bodies and/or necrotic debris that may serve to nucleate apatite at sites of injury.
(Reprinted from Giachelli CM, 2004)
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increased mortality. Second, osteogenic mechanisms may play a role in vascular calcification. It
has been observed that cells derived from the vascular media undergo a bone and cartilage-like
phenotypic change and calcification in vitro under various conditions (Giachelli, 2004, Allison et
al., 2006). Third, bone turnover leads to the release of circulation nucleational complexes and crystal growth. Lastly, cell death can provide phospholipid rich membranous debris and apoptotic bodies that may nucleate apatite, especially in patients with atherosclerosis, or other diseases where
necrosis and apoptosis occur. Elevated calcium and phosphorous levels promote apatite nucleation
and crystal growth to a point that would exacerbate vascular calcification initiated by any of the
other four previously mentioned conditions.
Effects of Calcium Supplementation
The link between vascular calcification and osteoporosis in postmenopausal women has
been associated with the third condition cited by Giachelli (2004), which is bone turnover. Elevated serum calcium levels accelerate vascular calcification and increase mortality in patients
(Bolland et al., 2010). Yang et al. (2004) experimented with smooth muscle cell culture systems.
He increased the calcium concentration of the media to hypercalcemic levels. The hypercalcemic
mixture led to enhanced mineralization and phenotypic transition of vascular smooth muscle cells.
The muscular cells underwent a phenotypic change in which they stopped expressing smooth
muscle specific genes and simultaneously expressed genes commonly associated with bone differentiation, including osteocalcin, osteopontin and Runx2 (cited in Giachelli 2004). In the a study of
Proudfoot et al. (2004) elevated calcium levels (1.8-to 5.0 mM) stimulated human smooth muscle
cell calcification in vitro. Calcification is also present in atherosclerotic lesions, thus raising the
possibility that increased calcium consumption may increase the risk of cardiovascular disease
(Bostick et al., 1999). When women consume calcium supplements, an increase in circulating
calcium levels may occur. This increase may possibly lead to myocardial infarctions and cardiovascular disease through the aforementioned mechanisms.
It has been suggested that calcium supplementation may lead to increased aortic valve
and coronary artery calcification (Messika-Zeitoun et al., 2006). Aortic valve and coronary artery
calcification are associated with cardiovascular risk factors. However, Bhakta et al. (2009) did not
find evidence that calcium supplementation would increase calcification in their independent assessments of aortic valve calcification and coronary artery calcification with calcium supplementation among patients older than sixty years old. Their study attempted to confirm whether calcium
supplementation increased the rate of aortic valve calcification and coronary artery calcification.
In their study of 257 patients, 144 were women. Twenty-five participants, all of them women,
reported using calcium supplements. Bhakta et al. (2009) did not observe a statistical increase in
aortic valve calcification or coronary artery calcification in the subgroup of women using calcium
supplementation. Additionally, there were no significant differences between the two groups regarding baseline serum calcium, renal function, diabetes, hypertension, and cholesterol or body
mass index. The presence of oral calcium supplementations was not associated with a statistically
accelerated aortic valve calcification or coronary artery calcification progression. However, the
results of this study are limited. First, since this study was not a clinical trial, beneficial or harmful
effects of therapeutic intervention cannot be ruled out. Second, due to the small sampling size of
25 women using calcium, it is impossible to generalize the study results to the larger population.
Yet, one advantage in this study is the use of Electron Beam Computed Tomography (EBCT),
which yields more exact results than an echocardiogram.
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In contrast, calcium has a lowering effect on the risk of cardiovascular disease and myocardial infarction. Firstly, calcium absorption has a beneficial effect on the high-density lipoprotein
cholesterol to low-density lipoprotein ratio in the body (Moyad 2003). The use of calcium supplements have been shown to increase that ratio of by almost 20% in healthy postmenopausal women.
Cholesterol changes of this magnitude may be associated with 20-30% reductions in vascular
event rates, such as myocardial infarction (Bolland et al., 2007). This increase of high lipoprotein
cholesterol results from calcium binding to fatty acids and bile acids in the gut, and leading to
a malabsorption of fat, as shown from studies of humans and animals. Calcium, if consumed in
quantities greater than the amount needed to maintain homeostasis, binds bile acids in the gut and
leads to their excretion. Calcium supplementation is therefore associated with an increased excretion of fecal bile acids. Bile acids-binding resins, such as cholestyramine, lower blood levels of
cholesterol, and is found to reduce the risk of ischemic heart disease (Bostick et al., 1999). Supplemental calcium was found to lower serum cholesterol in rats, rabbits, and goats as well, but not
young pigs. It may be suggested that that calcium supplementation would have similar effects on
humans.
Another positive reason to supplement with calcium, despite the consequences is that people living in calcium rich water areas have lower cardiovascular disease mortality than people utilizing soft water. Additionally, evidence suggests that calcium supplementation causes reduction in
blood pressure, although these reductions are small and transient. This may suggest that calcium,
through other mechanisms, generates a positive effect on the human cardiovascular system (Bolland et al., 2007).
Effect of Calcium Supplementation on the Risk of Cardiovascular Disease
Several large clinical studies were conducted to verify the effects of calcium supplements
on the cardiovascular system. The Women’s Health Initiative did the first and largest clinical experiment (LaCroix et al., 2009). They conducted a randomized control study of 36,282 postmenopausal women. Eligible postmenopausal women, ages 51-82, were randomly assigned to calcium
and vitamin D supplementation (calcium carbonate, 500 mg, with vitamin D3 200 IU, twice daily,
for a total of 1,000 mg calcium and 400 IU vitamin D3 per day) or to a placebo (Wactawski-Wende
et al., 2006). Concurrent calcium and vitamin D supplementation were permitted. The Women’s
Health Initiative concluded that amongst women younger than 70 years, calcium and vitamin
D supplementation appears to reduce risks of cardiovascular disease. However, the detection of
the benefits of calcium with vitamin D in this experiment is distorted. Sixty four percent of the
women in the placebo group had an intake of least 800 mg calcium per day and 42% had a daily
vitamin D intake of at least 400 IU from concurrent diet and supplementation allowed outside the
study. The low dose of 400 IU vitamin D per day may not be large enough to affect a change. Trials that have previously demonstrated benefits of calcium with vitamin D supplementation have
administered at least 700 IU per day to the patients (Hsia et al., 2007). Furthermore, more than
half of the participants in both groups were receiving hormone-replacement therapy (Finkelstein,
2006).
Adherence to the study drug was not complete, as only 60% of the study participants took
at least 80% of their study medication for the duration of an average of six years. Death caused by
myocardial infarction or coronary heart disease was confirmed in 499 women assigned to active
calcium/vitamin D and 475 assigned to a placebo (refer to table 1. on page 15). According to this
study, the risk of coronary heart disease, because of the use of active calcium/calcium and vita14

min D, is inversely related to bone mass index (BMI) (LaCroix et al,. 2009). Women with higher
BMI are at lower risk for coronary heart disease with active calcium/vitamin D supplementation,
whereas those with lower BMI were at higher risk. This aspect of the Women’s Health Initiative
observation is in line with that of The Kuopio Osteoporosis Risk Factor and Prevention Study
(2009), who also found that women with a higher BMI are at lower risk for cardiovascular disease.
However, after evaluating the risk of coronary cerebrovascular events in the Women’s
Health Initiative randomized trial of calcium plus vitamin D supplementation, Hsia et al. (2007),
did not find significant correlation between the risk of cardiovascular heart disease and calcium
supplementation. Temporal trends do not indicate a significant increase in the risk of coronary
heart disease over seven year’s time with calcium supplementation (Hsia et al., 2007).
There are several explanations to clarify the basis for the lack of difference observed between the calcium-supplemented group and the placebo group in Women’s Health Initiative study
on the risk of coronary heart disease. First, the use of personal supplements, as well as the poor
adherence to the study medication may have blurred the researchers from identifying the effect of
the study treatment. Second, the Women’s Health Initiative protocol led to only a small increase
in median plasma 25-hydroxyviamin D levels from 42.3 nmol/liter to 54.1nmol/liter. This is because the dose of vitamin D was inadequate to affect substantial change. In order to prove whether
vitamin D supplements affect cardiovascular disease, the women would require supplementation
of at least 1,000 IU vitamin D, thereby achieving the recommended level of 75 nmol/liter. By extrapolating this data, it can be inferred that Vitamin D supplementation at moderate to high doses
may have beneficial effects in reducing the risk for coronary heart disease (Hsia et al., 2007). In
contrast, calcium supplementation seems to have no apparent affect on the risk of cardiovascular
disease. A third explanation as to why the data of the Women’s Health Initiative is not valid is that
concurrent postmenopausal hormone therapy interfered with treatment effects. Most of all, cardiovascular heart disease was not the primary design of the study; the primary goal of the Women’s
Health Initiative trial was to determine the calcium and vitamin D component in causing hip fractures (McGowan and Pottern, 2000).

Calcium/Vitamin
D (N=18, 176), n
(Annualized %)

Placebo
(N=18,106) n
(Annualized %)

Hazard Ratio
(95% CI)

P=

Myocardial infarc- 499(0.39)
tion or CHD death

475(0.37)

1.04(0.92-1.18)

0.50

Myocardial infarc- 411(0.32)
tion

390(0.31)

1.05((0.91-1.2)

0.52

CHD Death

128(0.10)

1.01 (0.79-1.29)

0.92

130 (0.10)

Table 1. Cardiovascular Events by Treatment Group Assignment (cardiovascular event
includes coronary heart disease (CHD), and myocardial infarction.)
(Taken from Hsia, et al., 2007)

 	
A second study, the Iowa Women’s Health Study, was a cohort study of cancer incidence in
a sample of Iowa women. In 1986, 99,826 women aged 55-69 were invited to participate in an observational trial. A secondary study was conducted to determine the result of calcium supplementation. These women were mailed a questionnaire about sociodemographics, body measurements,
15

physical activity level, smoking and alcohol consumption, gynecologic history, dietary intake and
supplement use. A 127-Food-Item Harvard Food Frequency questionnaire was utilized to assess
these women’s usual food and nutrient intake. Forty-two percent of the women completed the
baseline questionnaire. The average age of the participants at baseline was 60.6 years, and 78.6 at
follow up. The Iowa Women’s Health Study confirms that many more women use calcium supplementation alone than calcium and vitamin D simultaneously (Refer to Table 2).
Baseline (1984)

Follow-up (2004)

% of women using
supplements

Number of women using
supplements

% of women using
supplements

Number of women using supplements

Calcium

46.2

8,474

60.4

11,078

Vitamin D

10.9

1,995

11.9

2.185

Table 2. This table shows the increase in the use of calcium/vitamin D
supplements over the twenty years and that many more women use
calcium, than Vitamin D.

One disadvantage of this study is that the questions on the follow-up questionnaire varied
from the initial assessment. For example, on the baseline questionnaire, vitamin D intake was inquired as an individual question. In contrast, the follow-up questioned the use of vitamin D supplements in a combined question of miscellaneous supplements. Although there were questions about
use ofvitamin supplements , the questionnaire did not ask about over-the-counter-medications or
herbal use. Certain non-food products, for example, Tums, contain nutrients that were not taken
into account.
The evidence of Park et al. (2009) demonstrates that women within the highest quartile of
calcium intake can reduce their risk of myocardial infarction by approximately 35%. They found
that calcium intake would reduce the risk, regardless of whether it is of dietary or supplementary
source or if taken together with vitamin D (reviewed in Bostick et al., 1999).
In contrast, the researchers of the Kupio Osteoporosis Risk Factor and Prevention Study
observed that calcium or calcium with vitamin D supplementation increases the risk of coronary
heart disease. Within a cohort of 10,555 women ages 52-62, over 25% reported use of calcium or
calcium plus vitamin D supplementation. Eight thousand, four hundred and twenty seven (8,427)
women, without a preexisting condition of coronary heart disease, were categorized as postmenopausal (Pentti et al., 2009). The criteria for coronary heart disease included: obvious symptoms of
angina pectoris, myocardial infarction, coronary artery bypass graft surgery, percutaneous balloon
angioplasty, chest pain, and significant coronary artery stenosis on a coronary angiography. During
the course of seven follow-up years, 513 cases of coronary heart disease were reported in the cohort of 10,555 women. Of the 513 cases, 424 were from the postmenopausal subgroup (n=8,424).
Three hundred and two cases of coronary heart disease occurred in postmenopausal women not
using calcium or vitamin D supplements; only 122 women who were using supplements developed
a condition. Many more nonusers of calcium supplements were diagnosed with coronary heart
disease than users of calcium or calcium and vitamin D. Interestingly, calcium-supplement users in
this study who had a lower BMI, with a mean of 26.3 kg/m²; were non-smokers or former smokers
than calcium supplement non-users; and had fewer childbirths than nonusers had. These differences provide an alternate explanation as to why more nonusers of calcium supplements developed
coronary heart disease, rather than concluding that it was specifically calcium/calcium plus vita16

min D that triggered these results. After considering all the variables that can affect the risk of heart
disease, the relative risk of developing coronary heart disease was 1.0 vs. 1.26, nonusers of supplements to users of supplements respectively. This statistical evidence demonstrates that the use of
calcium or calcium with vitamin D increased the risk of coronary heart disease in the subgroup of
postmenopausal women. It should be noted, however, that for women slightly after menopause,
calcium supplements did have a reducing affect on the risk of coronary heart disease. However, as
the years past menopause increased, so did the risk of a heart condition. The risk of cardiovascular
heart disease increased in women ages 60-62 by 61% with the use of calcium supplements (Pentti
et al., 2009). In addition to other drawbacks, this study could not determine coronary heart disease
morbidity, to the varied doses of calcium supplementation as the participants used products that
contained a wide range of doses of calcium. Again, this makes it impossible to verify whether
the increased coronary heart disease risk was solely related to calcium, or calcium and vitamin D
(Pentti et al., 2009).
Bolland et al. (2007) conducted a five-year randomized placebo-controlled study in New
Zealand to determine the effect of calcium supplementation on myocardial infarction, stroke, and
sudden death in healthy postmenopausal women. One thousand, four hundred and seventy one
(1,471) postmenopausal women (mean age 74) participated. Of those women 732 received calcium supplementation and 739 received placebos. Myocardial infarction occurred more often in
the calcium group than in the placebo group (45 events in 31 women vs. 19 events in 14 women).
Study participants were aged 55 or more, had been postmenopausal for a minimum of five years,
and had a life expectance of at least five more years. This study excluded women who were receiving treatment for osteoporosis, those with any major disease and women with serum 25-hydroxyvitamin D levels less than 25 nmol/l. Participants received 1,000 mg of elemental calcium
daily as citrate or an identical placebo. Ninety-percent of the women had a follow-up every six
months for five years. Cardiovascular events were self reported or reported by family members and
then verified.
3a. Number of women (number of events) self reported by patients or family 			
members.
Vascular Event 		
			
Myocardial Infarction
3b.

Calcium Group 		
31(45)		

Placebo Group
14(19)

Number of women (number of events) self reported or reported by family 			
members and verified.
Vascular Event		

Calcium Group

Myocardial Infarction

21(24)

Placebo Group
10(10)

3c. Number of women (number of events) self reported, reported by family
members and verified or not reported but confirmed by the national
database of hospitals admissions in New Zealand.
			
Vascular Event
Calcium Group
Placebo Group
		
Myocardial Infarction
31(36)
21(22)

Table 3. This table
depicts the difference between the
number of women
who experienced
myocardial
infarctions and the
number of total
events between the
calcium-supplemented group and the
placebo group (taken
from Bolland et al.,
2007).
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Initially, there seems to be a statistically significant increased number of myocardial infarctions in the calcium group compared to the number of infarctions in the placebo group. However,
after adjusting the data to include cardiovascular events not reported by participants or family
members, the increase was not substantial (refer to Table 3c.). When the data was evaluated as
event rates, the rate ratios for myocardial infarction were minimally significant. A notable difference was detected when the data for myocardial infarction was plotted over time. The numbers of
recorded cardiovascular events between the two groups began to diverge after about twenty-four
months, and thereafter continued to separate, although statistical significance was not attained.
In Bolland et al.’s 2007 study, the postmenopausal women had serum 25-hydroxyvitamin
D levels greater than 25 nmol/l. Participants received either 400 mg of elemental calcium as a
citrate, or a placebo. Results of this experiment show that although cardiovascular events, such
as angina and chest pain, did not differentiate greatly between groups, myocardial infarction and
transient ischemic attacks did have a significant statistical increase (refer to Table 3.c). There were
36 events of myocardial infarction in the calcium group, in contrast to 22 events of myocardial
infarction from women non-using calcium supplements.
Three years later, in 2010, Bolland et al. conducted a meta-analysis to reassess whether calcium supplements increase the risk of cardiovascular events in all patients; not specifically women.
After analyzing approximately 12,000 participants from 11 trials, seven of which were comprised
solely of females, the researchers concluded once again that calcium supplements, without coadministered vitamin D, increases the chances of cardiovascular events. Their research excluded
studies that incorporated vitamin D as a variable between the control group and calcium- supplemented group. Bolland et al. (2010) detected a 31% increase in the risk of incident myocardial infarction in the calcium-supplemented group. Calcium treatment was associated with an increased
risk of myocardial infarction in people with dietary calcium intake above the median of 805 mg/
day, but no increase was associated with participants with dietary intakes lower than the median.
Additionally, recurrent cardiovascular events were more common in the calcium-supplemented
group; 19 versus 13 cases of calcium supplemented women to non-supplemented women respectively had more than one cardiovascular event.
However, the trials considered in the study of Bolland et al. (2010) excluded trials in which
calcium and vitamin D were administered together against a placebo comparator, trials were only
eligible if vitamin D was given to both intervention and control groups, or to neither. Furthermore,
any trial in which calcium was administered in the form of dietary modification or a complex nutritional supplement was excluded from the study (Bolland et al., 2007). Since vitamin D supplementation has been associated with decreased mortality, the research of Bolland et al. (2007) does
not necessarily reflect the risk of cardiovascular disease among postmenopausal women taking
calcium supplementation alongside vitamin D.
The experimental data of Bolland et al. (2010) shows that if 69 people are administered
calcium, without co-administered vitamin D, one myocardial infarction will result. The risk of
myocardial infarction tended to be greater in those with dietary calcium intake above the median,
but independent of age, sex, and type of supplement. The finding of this study is consistent with
the conclusion of most of the trials analyzed by Bolland et al. (2010).
Bolland et al.’s (2007 and 2010) study results and conclusions differ from those of the
Women’s Health Initiative. Despite the great improvements observed in the ratio of high-density
lipoprotein cholesterol to low-density lipoprotein cholesterol, Bolland et al.’s studies (2007 and
2010) do not show any evidence that calcium supplementation may decrease the incidences of
18

vascular events. On the contrary, an increased risk for myocardial infarction is most noticeable in
those with high compliance with the study drug. Although this study does not completely prove
that calcium supplements can be detrimental to the cardiovascular system, it does suggest that administering calcium supplements is not a matter to be taken lightly.
There are several ways to explain the differing results of Bolland et al. and the Women’s
Health Initiative. Of the 1,471 participants in the study of Bolland et al. ( 2007), 105 women were
older than 80 years of age at baseline. Many other factors may have caused a myocardial infarction
in an elderly population other than calcium supplementation. Women participating in the Women’s
Health Initiative study were younger, with a mean age of 62, were heavier and had higher calcium
intakes on average. More importantly, the women in the Women’s Health Initiative took vitamin
D with calcium, and a majority of the women were undergoing hormone replacement therapy.
The women in Bolland et al.’s (2007) study did not use vitamin D supplements or oestrogen. Additionally, Bolland et al. (2007) conducted a randomized control study by dispensing large dose of
calcium citrate, a highly bioavailable calcium supplement that has already proven affects on bone
turnover and bone density. In contrast, the Women’s Health Initiative that used a low bioavailable
drug, calcium carbonate, had a lower compliance with the study drug, and their test results had to
compete with the effects of the use of oestrogen and non-trial supplements (Hsia et al., 2007).
Vitamin D and its Effect on Cardiovascular Disease
Oestrogen levels of postmenopausal women are constantly decreasing. Consequently, these
women are predisposed to osteoporosis. Vitamin D enhances intestinal absorption of calcium and
influences bone metabolism. Because Vitamin D supplementation is helpful in increasing bone
mineral density, it is beneficial to ingest vitamin D along with calcium. Therefore, postmenopausal
women are a primary concern for vitamin D deficiency (Gaugris et al., 2005). The question now is
whether co-administered vitamin D with calcium supplementation affects the risk of myocardial
infarction or heart disease. Various researchers have studied this subject and come to different
conclusions.
Stages of vitamin D
status

25(OH)D
concentrations
(nmol/l)

Biochemical/clinical symptoms

Deficiency

0-25

Severe hyperparathyroidism

Insufficiency

>25-50

Elevated PTH levels, low intestinal calcium absorption
rates, reduced bone mineral density, subclinical sympathy

Hypovitaminosis D

>50-70 to 100

Low body stores of Vitamin D, slightly elevated PTH

Adequacy

70-100 to 250

No disturbance of vitamin D-dependent functions

Toxicity

>250

Intestinal calcium hyperabsorption, hypercalcemia

Table 4. This table demonstrates that a deficiency of vitamin D leads to elevated
parathyroid hormone (PTH) levels and low intestinal calcium absorption
(Taken from Zittermann. 2006)

Parathyroid hormone maintains the short-term homeostasis of extracellular ionized plasma
calcium (ECF-Ca 2+) by increasing calcium re-absorption and mobilizing calcium from the labile
bone pool. The major control of ECF-Ca 2+ is through the renal production of 25(OH)2D. The
homeostasis of calcium ions is complex due to the influence of the gastrointestinal tract, the bones
19

and the kidneys. Once vitamin D is absorbed from one’s diet or produced by the skin from the
presence of sun exposure, it is metabolized in the liver to 25-hydroxyvitamin D. The kidney then
serves as the endocrine gland to produce the biologically active form of vitamin D. This active
form of vitamin D, 1-α,25-dihydroxyvitamin D3, is synthesized in the proximal tubule by the renal cytochrome P450 enzyme 25- hydroxyvitamin D3-1-α-hydroxylase. Additionally, the kidney
regulates the concentration of vitamin D through determining the final excretion of calcium ions in
the urine.
Homeostatic levels of calcium ions are necessary in order to insure normal bone mineralization (Hoenderop and Bindels, 2005). According to Hoenderop and Bindels (2005), The vitamin
D endocrine system is crucial for the proper development and maintenance of this Ca2+ homeostatic system. The homeostasis of extracellular ionized plasma calcium (ECF-Ca 2+) is tightly
regulated by a number of hormones, including Vitamin D. Vitamin D is transported to the liver,
binding to a specific α-globulin and to a small extent, albumin and lipoproteins. The vitamin is then
hydroxylated to calcidiol, 25-hydorxylated vitamin D- 25(OH)D. Afterwards, the vitamin D passes to the kidney where it is further hydroxylated to 1,25-dihydorxylated vitamin D- 1,25(OH)2D.
This active metabolite increases ECFCa2+ by increasing calcium and phosphate absorption from
the gut and mobilizing calcium from the bone (Sahota 2000).
Because 25(OH) D is the substrate for the renal enzyme that produces 1,25(OH)2D3, it
may have a direct and indirect effect on calcium absorption. A deficiency of vitamin D will reduce
the intestinal absorption of calcium (Diaz-Lopez and Cannata-Andia, 2006). Inadequate vitamin D
levels contribute to high levels of parathyroid hormone which lead to excessive bone remodeling
and ultimately to bone weakening (Wang et al., 2010). Moreover, excess parathyroid hormone levels increase blood pressure and cardiac contractility and leads to cardiomyocyte hypertrophy and
interstitial fibrosis of the heart. Thus, excess parathyroid hormone contributes to cardiovascular
disease. According to Jean et al. (2008), 25 (OH) D deficiencies may lead to mineralization and
bone formation defects. Vitamin D inhibits thrombosis and arterial calcification. It is therefore essential for calcium homeostasis and cardiovascular health.
It has been shown that women who use vitamin D supplements have a lower mortality
from cardiovascular disease than those that do not. For example, in a large cohort of 51,037 U.S.
patients receiving hemodialysis, those who received activated injectable vitamin D had lower cardiovascular disease mortality (7.6 per hundred-person years) than those who did not receive the
therapy (14.6 per hundred person-years) (Wang et al., 2010). The investigation of Bostick, et al.
(1999) on the Iowa Women’s Health Study showed similar results. However, although Bostick, et
al.’s (1999) study assessed nutrient intake by using questionnaires, and assessed the risk of cardiovascular disease by using predetermined endpoints, their study did not evaluate participants’
sun exposure and duration of supplement use. Additionally, an Australian study of elderly women
that compared the risk of ischemic heart disease between women assigned vitamin D placebo plus
calcium supplementation to those assigned to both vitamin D and calcium supplementation found
similar results (Wang et al. 2010).
One way to explain the lowered risk of cardiovascular disease among women using vitamin
D supplements in addition to calcium is that 1,25-vitamin D directly inhibits vascular calcification
(Zittermann, 2006). 1,25-vitamin D levels are inversely correlated with the extent of vascular calcification; the higher the intake of vitamin D, the less vascular calcification there will be (Watson
et al, 1997). Without sufficient vitamin D, women may not be able to absorb ample amounts of
calcium. Heaney et al. (2003) observed in their study of 34 postmenopausal women that the mean
20

calcium absorption under vitamin D repletion was 35.3% (+/-11.8) of the load and without supplemental vitamin D, 22.5% (+/-12.0) of the load. It is clear from their study that without sufficient
vitamin D, women will absorb a minimal amount of calcium.
Inadequate vitamin D intake seems to be associated with an increased risk for cardiovascular diseases. Should the hypothesis that vitamin D deficency contributes to cardiovascular disease
be true, perhaps cardiovascular mortality would be higher in countries of higher geographic latitude and vice versa.
CONCLUSION
Many researchers, such as those who conducted the Women’s Health Initiative and the
Iowa Women’s Health study, have concluded that calcium supplementation reduces the risk of
coronary heart disease, myocardial infarction and other cardiovascular related conditions. Others
did not observe a statistically important difference between the placebo and supplemented groups.
Finally, other researchers observed detrimental effects of calcium supplements on myocardial infarction rates, such as the study of Bolland et al. (2007 and 2010). However, even in the case study
of Bolland et al. (2010), the increased risk for myocardial infarction, in the calcium-supplemented
group was not statistically significant, once the values of myocardial infarction events were verified from the national database. Additionally, this study did not consider the effect of vitamin D as
a variable.
It may be suggested that calcium supplementation with co-administered vitamin D can
reduce the risk of cardiovascular disease. On the contrary, calcium supplementation, without coadministered vitamin D appears to have deleterious effects on cardiovascular disease. Further
research is required to understand better the mechanisms of calcification and the role of vitamin D
in calcium absorption, as it relates to lowering the risk of cardiovascular disease.
In conclusion, when women are treated with calcium, more instances of myocardial infarction will be caused than the number of symptomatic fractures that will be prevented (Bolland et al.,
2007). This statistical data brings to the forefront the idea that calcium supplementation in effort to
prevent osteoporosis, may not be an appropriate choice.
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